Brad Kahl
Professor of Medicine, Director of Lymphoma Program
Washington University School of Medicine · St. Louis, United States
Leading MCL clinical trialist at Washington University. Co-led key ECOG-ACRIN trials evaluating frontline strategies in MCL including lenalidomide combinations.
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
Blood advances · Feb 24, 2026
Converging approaches in the frontline treatment of mantle cell lymphoma.
Clinical advances in hematology & oncology : H&O · Nov 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy.
Clinical lymphoma, myeloma & leukemia · Jun 1, 2025
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Blood · Sep 5, 2024